Anna Tavridou PhD
 Assistant Professor of Pharmacology

Laboratory of Pharmacology, 
School  of Medicine, Democritus University of Thrace.


Telephone: +3025510-30530/ Fax  +3025510-30530

E-mail:   
atavrid@med.duth.gr

Address:

                 Laboratory of Pharmacology,
                 School of Medicine,
                 Democritus University of Thrace,
                 Dragana, Alexandroupolis,
                 68100, Greece.

 

Curriculum Vitae: 

 English Ελληνικά

 

     Research Interests:

 

  • Pathophysiology of atherosclerosis: in vitro studies (culturing of monocytes, hepatocytes, endothelial cells) and in vivo (animal models). Assessment of biomarkers for identifying subjects with atherosclerotic disease or involved in drug response.

  • Pathophysiology of osteoarthritis: study of cytokines in human biological samples and effect of drugs.

  • Mechanism of action of hypolipidemic, antihypertensive, antiatherosclerotic molecules.

  • Study of genetic polymorphisms involved in: a) the pathogenesis of cardiovascular and other disease, b) response to drugs targeting the cardiovascular and other systems, c) drug metabolism.

     Publications:

Tavridou A, Ragia G, and Manolopoulos VG (2011) Emerging targets for the treatment of dyslipidemia. Curr Med Chem 18:909-922

Tavridou A, Efthimiadis A, Efthimiadis I, and Manolopoulos VG (2010) Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. Heart Vessels 25:288-293

Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and Manolopoulos VG (2010) Endothelial nitric oxide synthase gene polymorphisms - 786T > C and 894G > T in coronary artery bypass graft surgery patients. Hum Genomics 4:375-383

Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and Manolopoulos VG (2010) Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. J Renin Angiotensin Aldosterone Syst 11:136-145

Manolopoulos VG, Ragia G, and Tavridou A (2010) Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 11:493-496

Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, and Manolopoulos VG (2010) Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend 108:70-76

Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, and Manolopoulos VG (2010) The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin Chim Acta 411:167-171

Tavridou A, and Manolopoulos VG (2009) Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369. Expert Opin Ther Pat 19:1473-1476

Tavridou A, and Manolopoulos VG (2009) EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Curr Pharm Des 15:3167-3178

Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, and Manolopoulos VG (2009) Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. Diabetes Res Clin Pract 84:132-137

Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, and Boudoulas H (2009) Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. Eur J Haematol 82:477-483

Ragia G, Petridis I, Tavridou A, Christakidis D, and Manolopoulos VG (2009) Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10:1781-1787

Ragia G, Arvanitidis KI, Tavridou A, and Manolopoulos VG (2009) Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10:43-49

Manolopoulos VG, and Tavridou A (2009) Drugs targeting atherosclerosis: current and emerging approaches. Curr Pharm Des 15:3091-3093

Tavridou A, and Manolopoulos VG (2008) Novel molecules targeting dyslipidemia and atherosclerosis. Curr Med Chem 15:792-802

Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2008) Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J Cardiovasc Pharmacol 51:573-580

Iordanidou M, Tavridou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V, Bougioukas G, and Manolopoulos VG (2008) The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians. Pharmacogenet Genomics 18:153-159

Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, and Manolopoulos VG (2007) EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium 14:239-243

Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2007) EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J Pharmacol Exp Ther 323:794-804

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, and Manolopoulos VG (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419-426

Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2006) Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol 535:34-42

Tavridou A, Efthimiadis A, Efthimiadis I, and Paschalidou H (2006) Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. Eur J Clin Pharmacol 62:485-489

Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, and Dionyssiou-Asteriou A (2005) Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:2740-2746

Tavridou A, and Manolopoulos VG (2005) Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes. Pharmacology 73:102-105

Tavridou A, and Manolopoulos VG (2004) Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Eur J Pharmacol 505:213-221

Tavridou A, Unwin N, Bhopal R, and Laker MF (2003) Predictors of lipoprotein(a) levels in a European and South Asian population in the Newcastle Heart Project. Eur J Clin Invest 33:686-692

Tavridou A, and Agius L (2003) Phosphorylase regulates the association of glycogen synthase with a proteoglycogen substrate in hepatocytes. FEBS Lett 551:87-91

Tavridou A, and Laker MF (1999) Field inversion gel electrophoresis for apolipoprotein(a) genotyping. Anal Biochem 272:282-285

Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, and Tavridou A (1999) Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 319:215-220

Tavridou A, Unwin NC, Laker MF, White M, and Alberti KG (1997) Serum concentrations of vitamins A and E in impaired glucose tolerance. Clin Chim Acta 266:129-140

Tavridou A, Avranas A, and Arzoglou P (1992) A mathematical approach to lipolysis based on the interrelationship of physicochemical and biochemical data. Biochem Biophys Res Commun 186:746-752

Lessinger JM, Tavridou A, Arzoglou P, and Ferard G (1992) Interest of using a purified, stable and commutable preparation of human pancreatic lipase in indirect assays. Analytical Letters 25:1453-1468

Arzoglou PL, Tavridou A, Lessinger JM, Tzimas G, and Ferard G (1992) Spectrophotometric determination of lipase activity in the presence of increased triolein concentration. Ann Biol Clin (Paris) 50:155-160

Arzoglou PL, Tavridou A, and Balaska C (1989) Rapid turbidimetric determination of lipase activity in biological fluids. Analytical Letters 22:1459-1470.


                                              Top